Crescent Biopharma said its independent Compensation Committee approved options covering an aggregate of 58,650 ordinary shares for two non-executive employees. The awards were approved on September 8, 2026, under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended, and were material to each employee's acceptance of employment under Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and an exercise price of $20.46, matching Crescent's Nasdaq closing price on September 8. For each grant, one-fourth of the shares will vest and become exercisable on the employee's first anniversary, followed by monthly vesting of one-forty-eighth of the shares, subject to continued service. Crescent is a clinical-stage biotechnology company developing cancer therapies, including a PD-1 x VEGF bispecific antibody and antibody-drug conjugates.